President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to repress his messaging.US Economyread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and its hurting America," he told Yahoo Finance Tuesday.Economyread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
The first debates will give most of the contenders their biggest platform yet to present themselves to the American people.Politicsread more
President Trump says "I hope we don't" have a war with Iran but it "would not last very long."Politicsread more
The stock market is shrinking for several key reasons, but there's a way for investors to maneuver it, says Citi Research strategist Robert Buckland.Trading Nationread more
Stocks rose on Wednesday as comments from Treasury Secretary Steven Mnuchin lifted expectations of a potential trade deal between China and the U.S.Marketsread more
Presidents Donald Trump and Xi Jinping are scheduled to meet Saturday, the second day of the two-day G-20 summit in Osaka, Japan.Politicsread more
A small group of companies have gotten so big that they are essentially becoming the market, and when they do well, the markets do well.Trader Talk with Bob Pisaniread more
Retailers can't let Amazon have all the sales on Prime Day. Target and eBay are two companies trying to compete.Retailread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition.
Roche said on Monday that both companies received a request for more information from the U.S. Federal Trade Commission in connection with the FTC's review of the deal.
Roche also said that the UK Competition and Markets Authority (CMA) has opened an investigation.
Roche wants to buy Spark to, among other things, get a hold of U.S. firm's experimental gene therapy for hemophilia A as well as its platform to develop other treatments for genetic diseases. But Roche has been forced to push back completion repeatedly, this time giving itself to July 31, beyond its self-imposed first-half deadline, to wrap things up.
"The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC in connection with its review," Roche said in a statement.
The FTC has said it does not comment on cases it is reviewing.
The British regulator's separate inquiry is aimed at determining whether the CMA considers it has jurisdiction over Roche's acquisition, and if so, whether it could hurt competition in Britain.
"Pending the outcome of its investigation, the CMA has issued an Interim Enforcement Order that would become effective upon closing of the transaction and would require Roche to hold separate the Spark business," Roche said. "The parties are working cooperatively with the CMA and will continue to do so."